Characterization of the nutrient assimilation pathways in M. tuberculosis

结核分枝杆菌营养同化途径的特征

基本信息

  • 批准号:
    10507765
  • 负责人:
  • 金额:
    $ 59.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-11-19 至 2025-10-31
  • 项目状态:
    未结题

项目摘要

Project Summary / Abstract Mtb utilizes host-derived lipids to promote pathogenesis and this is a defining feature of this intracellular pathogen. During infection Mtb imports and metabolizes host lipids to support pathogenesis by producing: i) energy, ii) central metabolic intermediates, or iii) polyketide virulence lipids. While the metabolic pathways in Mtb that degrade or process lipids are complex and contain redundant enzymes, the bacterial Mce lipid transporters appear to be specific for dedicated lipid substrates. Aim 1 of this work proposes to employ genetic and biochemical approaches to identify and characterize novel gene/proteins required for fatty acid import in Mtb. While it is understood that Mce1 imports fatty acids, the substrate specificity of this transporter is unknown. Therefore, we intend to define substrates and the biochemical basis of Mce1 substrate specificity. Our preliminary studies indicate that Mtb transports fatty acid precursors of immune signaling lipids via Mce1 and we include here studies to evaluate if scavenging of this immune lipid precursors by Mtb impacts the immune response. Aim 2 proposes to identify and characterize protein subunits that are shared by all the Mce transporters and are required for lipid import in Mtb. We have determined that LucA is required for Mce1- and Mce4-mediated transport and LucA stabilizes these transporter complexes. These studies seek to characterize the basis for this transporter stabilization. Similarly, MceG is required for Mce1- and Mce4-mediated transport and we intend to understand how MceG stabilizes and interacts with Mce1. We will use a genetic approach to silence LucA and MceG in Mtb within chronically infected mice and quantify bacterial fitness to determine the therapeutic potential of drugs that potentially block these proteins.
项目摘要/摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Brian C VanderVen其他文献

Brian C VanderVen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Brian C VanderVen', 18)}}的其他基金

Characterization of the nutrient assimilation pathways in M. tuberculosis
结核分枝杆菌营养同化途径的特征
  • 批准号:
    10304930
  • 财政年份:
    2020
  • 资助金额:
    $ 59.83万
  • 项目类别:
Preclinical evaluation of compounds that inhibit cholesterol uptake in M. tuberculosis.
抑制结核分枝杆菌胆固醇摄取的化合物的临床前评估。
  • 批准号:
    9448277
  • 财政年份:
    2017
  • 资助金额:
    $ 59.83万
  • 项目类别:
Preclinical evaluation of compounds that inhibit cholesterol uptake in M. tuberculosis.
抑制结核分枝杆菌胆固醇摄取的化合物的临床前评估。
  • 批准号:
    9759755
  • 财政年份:
    2017
  • 资助金额:
    $ 59.83万
  • 项目类别:
Preclinical evaluation of compounds that inhibit cholesterol uptake in M. tuberculosis.
抑制结核分枝杆菌胆固醇摄取的化合物的临床前评估。
  • 批准号:
    9571196
  • 财政年份:
    2017
  • 资助金额:
    $ 59.83万
  • 项目类别:
Preclinical evaluation of compounds that inhibit cholesterol uptake in M. tuberculosis.
抑制结核分枝杆菌胆固醇摄取的化合物的临床前评估。
  • 批准号:
    10237310
  • 财政年份:
    2017
  • 资助金额:
    $ 59.83万
  • 项目类别:
Exploiting metabolic toxicities to identify compounds that inhibit cholesterol metabolism in M. Tuberculosis
利用代谢毒性来识别抑制结核分枝杆菌胆固醇代谢的化合物
  • 批准号:
    9241338
  • 财政年份:
    2015
  • 资助金额:
    $ 59.83万
  • 项目类别:
Exploiting metabolic toxicities to identify compounds that inhibit cholesterol metabolism in M. Tuberculosis
利用代谢毒性来识别抑制结核分枝杆菌胆固醇代谢的化合物
  • 批准号:
    8940939
  • 财政年份:
    2015
  • 资助金额:
    $ 59.83万
  • 项目类别:
Analysis of host-derived nutrient utilization pathways in M. tuberculosis
结核分枝杆菌宿主来源的养分利用途径分析
  • 批准号:
    8442522
  • 财政年份:
    2013
  • 资助金额:
    $ 59.83万
  • 项目类别:
Analysis of host-derived nutrient utilization pathways in M. tuberculosis
结核分枝杆菌宿主来源的养分利用途径分析
  • 批准号:
    8613432
  • 财政年份:
    2013
  • 资助金额:
    $ 59.83万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 59.83万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 59.83万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 59.83万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 59.83万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 59.83万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 59.83万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 59.83万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 59.83万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 59.83万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 59.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了